SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2020-09-11
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter, phase 1 study of SyB C-0501 by continuous daily
oral administration in patients with advanced solid tumors, who have previously received
anticancer therapy and consists of two parts. Part 1 is a dose escalation study to evaluate
tolerability of SyB C-0501 in the patients, and to find the maximum tolerated dose (MTD),
recommended dose (RD) and optimum dosing schedule. Part 2 is being done to evaluate safety
and anti-tumor activity of SyB C-0501 preliminarily at RD, and to assess its target cancer
exploratory.